News and insights
-
New frontiers in inflammasome therapeutics
Insights from Atuka’s recent visit to the 6th Annual Inflammasome Summit in Boston.
-
Atuka releases its latest white paper, on the future of gene therapy
Building on Atuka’s pioneering work in Parkinson’s disease and other neurodegenerative disorders, this paper lays out the transformative potential of gene therapy.
—
-
Announcing a $1.5m collaboration with Kannalife Sciences and Michael J. Fox Foundation
The grant will fund preclinical research of Kannalife Science’s KLS-13019, a synthetic cannabinoid therapeutic which offers great promise for Parkinson’s disease.
—
-
What the market overlooked in Seelos’s recent trehalose study
Atuka’s Jonathan Brotchie and Patrick Howson take a deeper look at the top-line results for IV trehalose, an ALS treatment, and see signs of potential for the compound that the market may have missed.